• Home
  • The MMS Difference
    • About Us
    • Leadership
    • Certifications
  • Services
    • Regulatory Affairs and Operations
    • Data Management and Biostatistics
    • Regulatory and Medical Writing
    • Drug Safety and Pharmacovigilance
    • Compliance and Transparency
    • Data Sciences
  • Working with MMS
  • News and Media
  • MMS Blog
  • Careers
  • Contact Us
MMS
Part 2: The Case for Better Health History Records – How Much History is Needed and How Should it be Reviewed?

Part 2: The Case for Better Health History Records – How Much History is Needed and How Should it be Reviewed?

by Don McLean | Feb 21, 2019 | Blog

Part 2: The Case for Better Health History Records – How Much History is Needed and How Should it be Reviewed? by Barbara Rusin Part 1 of this medical histories series focused on the regulations relevant to clinical trial subject eligibility, and the possible issues...
Part 1: The Case for Better Health History Records – Regulatory Requirements

Part 1: The Case for Better Health History Records – Regulatory Requirements

by Don McLean | Aug 9, 2018 | Blog

Part 1: The Case for Better Health History Records – Regulatory Requirements by Barbara Rusin It is evident that during numerous audits, while working for the FDA and at MMS, clinical investigators are enrolling ineligible study subjects. A few of the ineligible...

Recent Posts

  • Unprecedented does not have to mean unprepared: Business Continuity Planning
  • Pharmaceutical Industry News Roundup: March 2020
  • MMS ANNOUNCES ONE MILLION DOLLAR AWARD FOR PHARMACEUTICAL COMPANIES DEVELOPING A VACCINE FOR COVID-19
  • The Circle of Concern vs the Circle of Influence: A Conversation with Dr. Uma Sharma
  • Committed to the health of your projects during COVID-19

Tags

ALZ awareness Alzheimers big data biosimilars biostatistics Clinical Development clinical research clinical study reports clinical trials clinical trial transparency Community Compliance COVID-19 CRO data management data privacy data science drug development EMA ENDALZ FDA Flint GDPR GXP auditing Health Analytics Collective Health Canada Lay summaries leadership medical writing NDA submission opioids pharma pharmacovigilance PhUSE Policy 0070 quality control real world data regulatory operations REMS resourcing statistical programming suicidality transparency trial regulation Volunteering